Results 231 to 240 of about 2,250,283 (269)

Toxicogenetics in drug development

Toxicology Letters, 2001
The major progress made in the understanding of the genetic basis of inter-individual variation in drug response, alongside the rapid advances in technology, provides major new opportunities to ensure the safe introduction of a new chemical entity into clinical practice.
B K, Park, M, Pirmohamed
openaire   +2 more sources

Drug Development and Regulation

Medicine, 2003
Abstract Models of drug development are moving away from those traditionally represented by large multinational pharmaceutical companies. The reasons for this trend and the likely shape of the pharmaceutical industry of the future are discussed here.
openaire   +1 more source

PET in drug development

2012 9th IEEE International Symposium on Biomedical Imaging (ISBI), 2012
Positron emission tomography (PET) is a tomographic imaging technique that allows for accurate non-invasive in vivo measurements of regional tissue function in man. It is the most selective and sensitive imaging modality able to measure molecular pathways and interactions in vivo at a picomolar level.
openaire   +1 more source

Drug development in neuropsychopharmacology

European Archives of Psychiatry and Clinical Neuroscience, 2008
Personalized medicine is still in its infancy concerning drug development in neuropsychopharmacology. Adequate biomarkers with clinical relevance to drug response and/or tolerability and safety largely remain to be identified. Possibly, this kind of personalized medicine will first gain clinical relevance in the dementias. The clinical relevance of the
openaire   +2 more sources

The Development of a Drug: A Pharmaceutical Drug Development Perspective

2020
Clinical investigation of New Molecular Entities (NME) in oncology is changing. Drivers of this transformation are advances in pharmacological platforms, such as antibody technology, changes in the regulatory framework to accelerate approval of new treatments, and rapid scientific discovery.
openaire   +1 more source

Radiotracers in Drug Development

2006
Although there are numerous books on drug metabolism, Radiotracers in Drug Development is unique in explaining how radiotracers are used to elucidate a drug’s absorption, distribution, metabolism, and excretion (ADME). Covering traditional and recent technologies and applications, the book takes a strong industrial approach, discussing the basics of ...
Graham Lappin, Simon Temple
openaire   +2 more sources

“Precision” drug development?

Clinical Pharmacology & Therapeutics, 2015
The concept of precision medicine has entered broad public consciousness, spurred by a string of targeted drug approvals, highlighted by the availability of personal gene sequences, and accompanied by some remarkable claims about the future of medicine. It is likely that precision medicines will require precision drug development programs.
openaire   +2 more sources

Antipsychotic Drug Development

2010
Schizophrenia typically manifests itself with a wide array of symptoms--positive, negative, cognitive, and affective--and may also involve neurodevelopmental and neurodegenerative aspects. Each of these symptom dimensions may be derived from pathology at one or more receptor types, localized in different regions of the brain.
Dennis H, Kim, Stephen M, Stahl
openaire   +2 more sources

Imaging in Drug Development

2015
Imaging has played an important part in the diagnosis of disease and development of the understanding of the underlying disease mechanisms and is now poised to make an impact in the development of new pharmaceuticals. This chapter discusses the underlying technologies that make the field ready for this challenge.
James, Nairne, Peter B, Iveson, Andreas, Meijer   +2 more
openaire   +2 more sources

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Cortes J, Roberto Carmagnani Pestana   +2 more
exaly